medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 1

<< Back Next >>

Ann Hepatol 2009; 8 (1)

Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C

Valverde BVMS, Takei K, Collarile YDC, Guz B, Strauss E

Language: Spanish
References: 37
Page: 26-31
PDF size: 115.89 Kb.


Text Extraction

Chronic hepatitis C (CHC) is one of the most important causes of chronic liver disease in the world, potentially resulting in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. Liver biopsy is currently performed before therapy indication. Although, it is the golden standard there are many reasons to avoid or delay the procedure. APRI Score is an easy, low cost and practice alternative method which was described as an alternative for assessing structural changes in chronic hepatitis C (CHC). The rationale of this study was to observe the accuracy of APRI Score in comparison to liver biopsy in 400 patients divided into two groups of 200 carriers (Validation and Experimental groups respectively) selected at random or according to liver fibrosis staging (METAVIR). The ROC curves showed a concordance among these two methods of 92% and 88.5% when 1.05 was the cut off (F3 and F4), and 87% and 83%, on 0.75 cut offs (F2-F4). The discordance in advanced fibrosis staging (F3 and F4) was only 16 (8%) and 22 (11%) out of 200 patients in the experimental and validation groups, respectively. In 26 (13%) out of 200 patients in the experimental group and 34 (17%) out of 200 patients in the validation group, there was discordance between APRI Score and liver biopsy in moderate and advanced fibrosis (F2-F4). In conclusion APRI is a serological marker that has satisfactory sensitivity and specificity together with a high predictive value and it can be useful either in the absence of a biopsy or to reduce the frequency with which biopsies need to be carried out to monitor the evolution of chronic hepatitis C and the right moment for treatment indication.


REFERENCES

  1. Cadranal JF, Rufat P, Degos F. Practices of liver biopsy in France: results of prospective nationwide survey. Hepatology 2000; 32: 477-481.

  2. Dienstage JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152-S160.

  3. Regev A, Behro M, Jeffers LJ, Milikowski , Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intra observer variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.

  4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.

  5. Cadranel IF. [Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future]. Gastroenterol Clin Biol 2002; 26(10): 823-824.

  6. Wai CT, Greenson JL, Fontana RJ, Kalbfleich JD, Marrero JA, Conjeevaram HS, Lok AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  7. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.

  8. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel AIDS 2007; 21(9): 1073-89.

  9. Asselah T, Biéche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: Implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27(1): 13-27.

  10. Lamn SL, Tram T, Zein NN. AASLD 2007: The future of hepatitis C Therapeutics. 2007{cited 2007 December 17}. Available from://cme.medscape.com/viewprogram/8292.pdf

  11. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. AM J Gastroenterol 2004; 99: 1160-1174.

  12. Poynard, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349(9055): 825-32.

  13. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.

  14. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568-71.

  15. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59.

  16. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S.

  17. Alberti A, Sebastiani G. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694.

  18. Parise ER, Oliveira AC, Figuerêdo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006; 26(9): 1095-1099.

  19. Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in hepatitis C. World J Gastroenterol 2007. 28: 13(32): 4287-4294.

  20. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.

  21. Borroni G, Ceriani R, Cazzaniga M, Tommasini M, Roncalli M, Maltempo C, Felline C, et al. Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Aliment Pharmacol Ther 2006; 24(5): 797-804.

  22. Snyder N, Hawari R, Xiao S-Y, Lau D, Soloway R, Petersen J. What are the best cut offs for the APRI. Gastroenterol 130: A-79.

  23. Viana MSVB, Barcelos LCP, Gonçalves DM, Sipahi HM, Guz B. APRI Score (AST Platelet Ratio Index) na hepatite crõnica por vìrus C – Estudo Piloto. GED 2005; 24(2): PO-261, S6823.

  24. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotranferase-alanine aminotranferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic disease. Arch Intern Med 2003; 163: 218-224.

  25. Gibson PR, Fraser JR, Brown TJ, Finch CF, Joses PA, Colman JC, Dudley FJ. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15(6): 1054-1059.

  26. Halfon P, Bourliére M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Alliere, Ouzan D. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Hepatology 2005; 4: 6.

  27. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25(5): 684-688.

  28. Oh S, Afdal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001; 3: 12.

  29. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-33.

  30. Höroldt B, Haydon G, O Donell K, Dudley T, Nighngale P, Multimer D. Results of combination treatment pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int 2006; 26(8): 650-659.

  31. Ono E, Shiratori Y, Okudaira T. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192-200.

  32. Taniguchi H, Isawaki Y, Fujiwara A, Sakaguchi K, Morya A, Piao CY, Takaki A, et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol and Hepatol 2006; 21(2) n1: 281-287.

  33. Castera L, Verniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343-50.

  34. Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol and Hepatol 2005; (2): S89-91.

  35. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Gurgrah N, Yoshida E, et al. Management of chronic hepatitis C: Consensus guideline. Can J Gastroenterol 2007; (21)Suppl C: 25C-34C.

  36. Pereira HMV, Cavalheiro NP, Tengan FM, Melo CE, Mello ES, e Baroni AA. Patients with chronic hepatitis C and normal transaminases. Rev Inst Med Trop S. Paulo 2005; 47(5): 247-25.

  37. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, et al. Are noninvasive liver fibrosis tests ready for use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J of Hepatol (In Press).




2020     |     www.medigraphic.com